EE303 Cost-Effectiveness Analysis of Pd-L1 Testing Associated with Pembrolizumab for First-Line Treatment of Advanced NSCLC in China
Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.604
https://www.valueinhealthjournal.com/article/S1098-3015(23)00704-0/fulltext
Title :
EE303 Cost-Effectiveness Analysis of Pd-L1 Testing Associated with Pembrolizumab for First-Line Treatment of Advanced NSCLC in China
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)00704-0&doi=10.1016/j.jval.2023.03.604
First page :
Section Title :
Open access? :
No
Section Order :
10088